Faculty

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC)

• Optimal approaches to biomarker testing for patients with newly diagnosed advanced OC; significance of somatic and germline BRCA mutations and homologous recombination deficiency status in treatment decision-making
• Long-term findings, including overall survival (OS) outcomes, with olaparib, olaparib/bevacizumab and niraparib maintenance therapy for patients with newly diagnosed OC
• Clinical, biological and practical factors in the selection of up-front maintenance olaparib, olaparib/bevacizumab or niraparib
• Ongoing Phase III studies, such as MONO-OLA1 and NRG-GY036, further exploring up-front PARP inhibitor maintenance therapy
• Current clinical utility, if any, of PARP inhibitors for patients with relapsed/refractory OC, including those who have experienced disease progression after PARP inhibitor therapy

MODULE 2: Strategies Targeting Folate Receptor Alpha (FRα) in Advanced OC

• Incidence and clinical relevance of FRα expression in OC; optimal approaches to and timing of FRα testing
• Long-term data, including OS findings, with mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant OC from the Phase III MIRASOL trial; optimal integration into current management algorithms
• Key findings from the Phase II PICCOLO and MIROVA trials of mirvetuximab soravtansine for FRα-positive, platinum-sensitive OC; potential clinical role
• Design, eligibility criteria and primary and secondary endpoints of the Phase III GLORIOSA trial evaluating mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-positive OC who have not experienced disease progression after second-line platinum-based chemotherapy and bevacizumab
• Mechanistic similarities and differences between investigational FRα-targeted antibody-drug conjugates, such as rinatabart sesutecan, torvutatug samrotecan and sofetabart mipitecan, and mirvetuximab soravtansine
• Early data with and ongoing evaluation of investigational FRα-targeted antibody-drug conjugates for FRα-expressing, platinum-resistant OC

MODULE 3: Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC

• Frequency of HER2 expression in advanced OC; outcomes observed among patients with OC in the Phase II DESTINY-PanTumor02 trial of trastuzumab deruxtecan (T-DXd) for pretreated HER2-expressing solid tumors
• Recent tumor-agnostic FDA approval of T-DXd and implications for OC management
• Ongoing Phase III DESTINY-Ovarian01 trial seeking to further define the role of T-DXd in therapy for advanced OC
• Rationale for targeting CDH6 in advanced OC; mechanism of antitumor activity of raludotatug deruxtecan (R-DXd)
• Available research findings, including those from the Phase II dose-optimization part of the ongoing Phase II/III REJOICE-Ovarian01 study, with R-DXd for patients with platinum-resistant advanced OC
• FDA breakthrough therapy designation of R-DXd for patients with platinum-resistant epithelial OC expressing CDH6 who have received prior treatment with bevacizumab; potential clinical role
• Early efficacy and safety outcomes with and ongoing evaluation of TROP2-directed antibody-drug conjugates for patients with advanced OC
• Other promising targets for antibody-drug conjugates, such as B7-H4, under investigation for patients with advanced OC

MODULE 4: Other Novel Agents and Strategies for Advanced OC

• Mechanism of antitumor activity of the selective glucocorticoid receptor modulator relacorilant and rationale for its evaluation for advanced OC
• Published efficacy and safety findings from the Phase III ROSELLA study of relacorilant and nab paclitaxel versus nab paclitaxel alone for patients with platinum-resistant advanced OC
• Tolerability profile of relacorilant/nab paclitaxel in the ROSELLA trial; relative contributions of each agent with regard to toxicities
• Recent FDA approval of relacorilant/nab paclitaxel for platinum-resistant advanced OC; integration into current clinical algorithms
• Available data, including OS outcomes, from the Phase III KEYNOTE-B96 study evaluating the addition of pembrolizumab to chemotherapy with or without bevacizumab for patients with platinum-resistant recurrent OC
• Recent FDA approval of pembrolizumab in combination with chemotherapy with or without bevacizumab and current clinical role in therapy for platinum-resistant recurrent OC

MODULE 5: Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC

• Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors for OC
• Optimal monitoring, mitigation and management approaches for common PARP inhibitor-related toxicities
• Reported risk of long-term, serious side effects, such as myelodysplastic syndromes or acute myeloid leukemia, with PARP inhibitor therapy
• Pathogenesis and incidence of ocular adverse reactions associated with mirvetuximab soravtansine; recommended approaches to prevention, monitoring and management
• Spectrum, frequency, severity and management of other side effects, such as peripheral neuropathy, gastrointestinal (GI) toxicities, fatigue and pneumonitis, in patients receiving mirvetuximab soravtansine
• Spectrum and incidence of common (eg, GI toxicities, myelosuppression) and more serious (eg, interstitial lung disease, cardiac toxicities) treatment-emergent adverse events observed with T-DXd
• Recommended strategies to monitor for, mitigate and manage T-DXd-associated toxicities

Target Audience
This activity is intended for medical and gynecologic oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ovarian cancer (OC).

Learning Objectives
Upon completion of this activity, participants should be able to 

• Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced OC, and appropriately counsel patients regarding personalized treatment recommendations.
• Appraise biological and patient- and treatment-related factors in order to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
• Recognize the rationale for targeting folate receptor alpha (FRα) in OC, and understand the mechanism of action of and available research findings with FRα-directed antibody-drug conjugates (ADCs).
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with platinum-resistant OC, and consider the current role of this novel therapeutic strategy.
• Understand the biological justification for the evaluation of selective glucocorticoid receptor modulators in combination with chemotherapy for patients with platinum-resistant OC, and recall available Phase III findings with this novel approach.
• Assess the incidence of cadherin-6 expression in OC, and understand the structural components of, mechanism of action of and available data with novel ADCs directed at this target.
• Review published clinical research findings documenting the efficacy of HER2-targeted agents and regimens in patients with HER2-overexpressing OC and other gynecologic cancers, and consider the role of ADCs and other approaches.
• Describe the scientific justification for, published research data with and current research studies of other novel agents and strategies in OC, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Eskander — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Foundation Medicine, Gilead Sciences Inc, GSK, ImmunoGen Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MSD, Myriad Genetic Laboratories Inc, Natera Inc, Novocure Inc, Pfizer Inc, pharmaand GmbH, PMV Pharma, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Data and Safety Monitoring Boards/Committees: Xencor. Dr Matulonis — Advisory Committees: AbbVie Inc, Ascendis Pharma, Corcept Therapeutics Inc, Day One Biopharmaceuticals, GSK, Kaida BioPharma, Merck, NextCure, Whitehawk Therapeutics; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, MacroGenics Inc, Mural Oncology Inc, Symphogen A/S. Dr Olawaiye — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, GSK, Lilly, Merck; Consulting Agreements: Corcept Therapeutics Inc; Speakers Bureaus: Foundation Medicine. Dr O’Malley — Consulting Agreements — Personal Fees (Consult and/or Advisory Boards): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, Genmab US Inc, GSK, Lilly, Merck, MSD, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds for Research): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, MSD, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, pharmaand GmbH, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Pharma America, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Data and Safety Monitoring Boards/Committees: Frantz Viral Therapeutics. Additional faculty to be announced.

MODERATOR — Dr Moore — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, GSK, Mersana Therapeutics Inc; Consulting Agreements: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, GSK, ImmunoGen Inc, Janssen Biotech Inc, Merck, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Whitehawk Therapeutics, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Accent Therapeutics, Advaxis Inc, Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GSK, Immunocore, Iovance Biotherapeutics, Regeneron Pharmaceuticals Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics; Nonrelevant Financial Relationships: ASCO, GOG Partners, NRG Oncology.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:30 PM on Saturday, May 30th. If you are interested in attending, please visit the registration desk outside Continental Room C (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Faculty

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:30 PM — Educational Meeting

MODULE 1: Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

• Clinical, biological and practical factors in the selection of front-line therapy for patients with CLL requiring treatment
• Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for treatment-naïve and relapsed/refractory (R/R) CLL; application in current up-front decision-making
• Pharmacological similarities and differences between covalent and noncovalent BTK inhibitors
• Key findings from the Phase III BRUIN CLL-314 study of pirtobrutinib versus ibrutinib for patients with treatment-naïve or previously treated, BTK inhibitor-naïve CLL
• Published data with pirtobrutinib versus bendamustine/rituximab for patients with treatment-naïve CLL without del(17p) in the Phase III BRUIN CLL-313 trial
• Potential clinical role of pirtobrutinib in therapy for newly diagnosed CLL

MODULE 2: Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL

• Long-term data with up-front venetoclax/obinutuzumab for CLL
• Mechanistic rationale for combining BTK inhibitors and venetoclax with and without anti-CD20 antibodies for CLL
• Published findings from the Phase III AMPLIFY trial of fixed-duration acalabrutinib in combination with venetoclax with or without obinutuzumab for previously untreated CLL
• Recent FDA approval of fixed-duration acalabrutinib and venetoclax for patients with treatment-naïve CLL; integration into current clinical algorithms
• Early data with zanubrutinib in combination with Bcl-2 inhibitors, such as venetoclax or sonrotoclax, with or without an anti-CD20 antibody, for treatment-naïve CLL
• Efficacy and safety findings from and clinical implications of the Phase III CLL17 trial evaluating fixed-duration versus continuous targeted treatment for previously untreated CLL

MODULE 3: Optimal Management of Adverse Events (AEs) with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations

• Relevant patient comorbidities, such as hypertension, preexisting cardiac arrhythmias, chronic kidney disease and chronic migraines, and concomitant medications that might influence the choice of therapy for CLL
• Spectrum, frequency and severity of cardiovascular AEs with covalent and noncovalent BTK inhibitors; optimal monitoring and management protocols
• Incidence and management of noncardiovascular AEs associated with covalent and noncovalent BTK inhibitors
• Frequency of tumor lysis syndrome and other common AEs reported with venetoclax for CLL, such as cytopenias, infections and gastrointestinal disorders; monitoring, prophylaxis and management protocols
• Incidence, severity and management of clinically relevant toxicities encountered when combining BTK and Bcl-2 inhibitors with or without anti-CD20 antibodies

MODULE 4: Selection and Sequencing of Therapy for R/R CLL

• Clinical and biological factors guiding decision-making for patients with R/R CLL; impact of the evolving up-front CLL treatment paradigm on the management of R/R disease
• Long-term follow-up from Phase III trials evaluating covalent BTK inhibitors and Bcl-2 inhibitors for patients with R/R CLL; current role of rechallenge with an agent or class of agents received in a prior line of therapy
• Published findings from key trials, such as BRUIN and BRUIN CLL-321, supporting the use of pirtobrutinib for patients with R/R CLL
• Emerging positive findings from the Phase III BRUIN CLL-322 trial of pirtobrutinib in combination with venetoclax and rituximab versus venetoclax and rituximab for patients with R/R CLL
• Available and emerging efficacy and safety data with and ongoing evaluation of other noncovalent BTK inhibitors, such as nemtabrutinib and rocbrutinib, for R/R and treatment-naïve CLL

MODULE 5: Other Novel Strategies for CLL

• Biological rationale for the evaluation of CAR T-cell therapy in CLL
• Published efficacy and safety findings with lisocabtagene maraleucel (liso-cel) for R/R CLL from the Phase I/II TRANSCEND CLL 004 trial
• FDA approval of liso-cel for CLL previously treated with a BTK inhibitor and a Bcl-2 inhibitor; current clinical role and optimal patient selection
• Early antitumor activity and safety data with bispecific antibodies for R/R CLL and CLL with Richter’s syndrome
• Rationale for the design of the ongoing Phase III SOUNDTRACK-C1 study of the CD19 x CD3 bispecific T-cell engager surovatamig as consolidation therapy for patients with IGHV-unmutated CLL
• Preliminary data with and ongoing Phase III trials of other promising novel agents and strategies, such as sonrotoclax and BTK degraders, for patients with CLL  

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to 

• Individualize the selection of systemic therapy for patients with newly diagnosed CLL, considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
• Evaluate available and emerging Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options.
• Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for newly diagnosed and relapsed/refractory CLL, and identify patients appropriate for treatment with these agents.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented and emerging data with and the current and potential role of this strategy for patients with newly diagnosed and relapsed/refractory CLL.
• Evaluate the biological rationale for the investigation of CD19-directed chimeric antigen receptor T-cell therapy for CLL, and identify patients for whom treatment with this novel therapeutic strategy would be appropriate.
• Recall available data with novel agents and combination strategies currently under investigation for CLL, and as applicable, discuss clinical trial participation with eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Allan — Advisory Committees: NeoGenomics; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company; Contracted Research: Adaptive Biotechnologies Corporation, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: Merck; Speakers Bureaus: AbbVie Inc, BeOne. Dr Fakhri — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, BeOne, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company. Dr Ma — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Lilly; Consulting Agreements: AbbVie Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Carna Biosciences, Juno Therapeutics, a Celgene Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, BeOne, Lilly. Dr Shadman — Advisory Committees and Consulting Agreements: AbbVie Inc, ADC Therapeutics, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Merck, MorphoSys, Nurix Therapeutics Inc, Pfizer Inc, Pierre Fabre; Contracted Research: AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Merck, MorphoSys, Nurix Therapeutics Inc, Sana Biotechnology; Stock OPTIONS — Private Companies: Koi Biotherapeutics Inc; Nonrelevant Financial Relationships: Bristol Myers Squibb (spouse employment).

MODERATOR
Dr Abramson — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Celgene Corporation, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Interius BioTherapeutics, Miltenyi Biotec, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Lilly.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room B (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:00 PM on Friday, May 29th. If you are interested in attending, please visit the registration desk outside Continental Room B (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Faculty

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:30 PM — Educational Meeting

MODULE 1: Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

• Long-term outcomes observed with up-front osimertinib monotherapy for patients with metastatic EGFR-mutated NSCLC
• Major efficacy and safety findings, including outcomes from the final overall survival (OS) analysis, from the Phase III FLAURA2 trial of osimertinib combined with chemotherapy versus osimertinib alone as first-line treatment for EGFR-mutant NSCLC
• Extended follow-up, including published OS findings, from the Phase III MARIPOSA trial of up-front treatment with amivantamab/lazertinib or lazertinib alone versus osimertinib for patients with metastatic EGFR-mutant NSCLC
• Documented CNS activity of osimertinib/chemotherapy and amivantamab/lazertinib in EGFR-mutated advanced NSCLC
• Optimal selection of patients with newly diagnosed EGFR-mutated NSCLC to receive osimertinib/chemotherapy and amivantamab/lazertinib

MODULE 2: EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC

• Key data from the Phase III MARIPOSA-2 study supporting the FDA approval of amivantamab in combination with platinum-based chemotherapy for patients with progressive EGFR-mutated advanced NSCLC
• Optimal incorporation of amivantamab/chemotherapy into current management algorithms
• Efficacy and safety outcomes documented with a subcutaneous formulation of amivantamab in combination with lazertinib in refractory and treatment-naïve EGFR-mutated advanced NSCLC
• Available findings from the COMPEL trial comparing platinum-based chemotherapy with and without osimertinib for patients with EGFR-mutated advanced NSCLC and non-CNS disease progression on first-line osimertinib
• Early data with and ongoing studies combining osimertinib with other systemic therapies in order to overcome common mechanisms of resistance

MODULE 3: Utility of TROP2-Targeted Antibody-Drug Conjugates (ADCs) in the Management of EGFR-Mutant NSCLC

• Mechanism of antitumor activity of datopotamab deruxtecan (Dato-DXd) and rationale for its investigation in pretreated EGFR-mutant NSCLC
• Antitumor activity observed with Dato-DXd in patients with previously treated EGFR-mutated NSCLC in a pooled analysis of the TROPION-Lung05 and TROPION-Lung01 trials
• Recent FDA approval of Dato-DXd for EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy; current role of this strategy
• Intracranial activity of Dato-DXd in patients with NSCLC and brain metastases; implications for its utility in pretreated EGFR-mutant disease
• Published data with and ongoing evaluation of other TROP2-targeted antibody-drug conjugates (eg, sacituzumab tirumotecan) for EGFR TKI-resistant, EGFR-mutated advanced NSCLC

MODULE 4: Emerging Role of Bispecific Antibody-Based Approaches in the Treatment of EGFR-Mutated NSCLC

• Available data with and current role, if any, of immune checkpoint inhibitors in therapy for patients with NSCLC and EGFR mutations
• Mechanism of antitumor activity of the PD-1 x VEGF bispecific antibody ivonescimab; rationale for its investigation in pretreated EGFR-mutant NSCLC
• Design, eligibility criteria and efficacy and safety findings from the Phase III HARMONi trial evaluating ivonescimab in combination with carboplatin and pemetrexed for patients with EGFR-mutated NSCLC after disease progression on a third-generation TKI
• Recent acceptance of a biologics license application for ivonescimab/chemotherapy for pretreated EGFR-mutated NSCLC; potential role in clinical practice
• Structural components and mechanism of action of the first-in-class bispecific antibody-drug conjugate izalontamab brengitecan (iza-bren)
• Available research data with and ongoing evaluation of iza-bren for patients with NSCLC harboring EGFR mutations

MODULE 5: Tolerability Considerations with Available and Emerging Therapies for NSCLC with EGFR Mutations

• Comparative tolerability profiles of osimertinib/chemotherapy and amivantamab/lazertinib; implications for the selection of first-line therapy for EGFR-mutant metastatic NSCLC
• Optimal approach to preventing infusion-related reactions with amivantamab; relevant findings from the Phase II SKIPPirr study
• Results from the Phase II COCOON study evaluating the impact of enhanced versus standard dermatologic management on the incidence of dermatologic adverse events (AEs) for patients with EGFR-mutated metastatic NSCLC who receive first-line amivantamab/lazertinib
• Spectrum, frequency and severity of toxicities reported with Dato-DXd for patients with EGFR-mutant advanced NSCLC
• Recommended algorithms for monitoring for, mitigating and managing common and more serious AEs documented with Dato-DXd
• Frequency, severity and management of toxicities associated with ivonescimab

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to 

• Counsel patients with newly diagnosed metastatic EGFR-mutated non-small cell lung cancer (NSCLC) regarding available therapeutic considerations, explaining the relevance of mutation type, symptomatology, sites and extent of metastases, prior therapeutic exposure and other factors.
• Appreciate the biological rationale for dual inhibition of MET and EGFR for patients with EGFR-mutated NSCLC, and understand recently presented data establishing the benefit of this strategy.
• Evaluate the documented efficacy of chemotherapy combined with EGFR-targeted therapy, and consider the current role of available approaches in both the front-line and relapsed/refractory settings for patients with metastatic NSCLC and EGFR mutations.
• Review published research findings with TROP2-directed antibody-drug conjugates for patients with metastatic NSCLC and EGFR mutations, and optimally incorporate these agents into treatment algorithms.
• Appraise the scientific rationale for the development of bispecific antibodies directed at PD-1 x VEGF, and reflect on the potential role of these agents in the management of EGFR-mutated NSCLC.
• Recall the biological rationale for the evaluation of various novel therapeutic approaches for patients with NSCLC and EGFR mutations.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — Prof Passaro has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Goldberg — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BlossomHill Therapeutics, Daiichi Sankyo Inc, Johnson & Johnson, Lilly, Merck, Regeneron Pharmaceuticals Inc, Summit Therapeutics, Synthekine, Tubulis; Contracted Research: Adela, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Mirati Therapeutics Inc; Data and Safety Monitoring Boards/Committees: Daiichi Sankyo Inc. Dr Goldman — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pfizer Inc, Summit Therapeutics; Contracted Research: AbbVie Inc, Agenus Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Puma Biotechnology Inc, RayzeBio, Summit Therapeutics, Tango Therapeutics. Dr Neal — Advisory Committees (Consulting and Advisory): AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Iovance Biotherapeutics, Janssen Biotech Inc, Lilly, Natera Inc, Novartis, Novocure Inc, Nuvation Bio Inc, Oxford BioTherapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Summit Therapeutics, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Adaptimmune, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Lilly, Merck, Novartis, Nuvalent, Revolution Medicines Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Stock Options/Stock — Public Companies: SecondLook Health.

MODERATOR
Dr Sands — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Catalyst Pharmaceuticals Inc, Daiichi Sankyo Inc, Fosun Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Lilly, Merck, Novartis, Pfizer Inc, PharmaMar, Sanofi; Contracted Research: Amgen Inc, Novartis.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Johnson & Johnson.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room A (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Thank you for your interest in our CME program taking place in Chicago. Online registration for in-person attendance is now closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.

Our onsite registration desk will open at 6:00 PM on Friday, May 29th. If you are interested in attending, please visit the registration desk outside Continental Room A (Lobby Level) at the Hilton Chicago hotel (720 South Michigan Avenue, Chicago, IL 60605).

Please note that onsite registration does not guarantee seating or participation in the meal service, which will be based on availability.

If you have any questions, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Part 2 of a 2-Part CME Satellite Symposium Series Held in Conjunction with the 2026 American Urological Association Annual Meeting (AUA2026)

Location
Walter E Washington Convention Center
801 Allen Y Lew Place NW
Washington, DC 20001
Phone: (202) 249-3000

Program Schedule — Eastern Time
5:00 PM – 5:30 PM — Registration and Dinner
5:30 PM – 7:30 PM — Educational Meeting

Meeting Room
Ballroom A, Third Level

No registration fee is charged for this event. For the in-person symposium in Washington, DC, preregistration is required to ensure seating.

Faculty

Program Schedule — Eastern Time
5:00 PM – 5:30 PM — Registration and Dinner
5:30 PM – 7:30 PM — Educational Meeting

MODULE 1: Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (nmHSPC) — Dr Shore

• Rationale for the evaluation of treatment intensificationwith androgen receptor (AR) pathway inhibitors for nmHSPC
• Major efficacy and safety data, including overall survival outcomes, from the Phase III EMBARK trial evaluating enzalutamide with leuprolide versus enzalutamide or leuprolide alone for patients with nmHSPC and high-risk biochemical recurrence after definitive therapy
• FDA approval of enzalutamide with and without androgen deprivation therapy (ADT) and optimal application in clinical practice
• Published data with ADT intensification with apalutamide with or without abiraterone for patients with high-risk, biochemically recurrent nmHSPC
• Other ongoing Phase III studies evaluating AR pathway inhibitors for patients with nmHSPC

MODULE 2: Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak

• Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for patients with mHSPC
• Published data from the Phase III ARANOTE study supporting the recent FDA approval of darolutamide/ADT for mHSPC
• Clinical factors guiding the selection of a specific AR pathway inhibitor for patients with mHSPC; availabledatasets exploring the relative benefit of various approved agents
• Published efficacy and safety data from the Phase III ARASENS trial evaluating darolutamide in combination with docetaxel and ADT for mHSPC
• Selection of optimal candidates with mHSPC for triplet therapy with darolutamide/docetaxel/ADT

MODULE 3: Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal

• Incidence and clinical implications of BRCA1/2 and other homologous recombination repair (HRR) abnormalities in patients with mPC; recommended timing and optimal method for genetic testing
• Long-term efficacy and safety findings with olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide, respectively, in the first-line setting for metastatic castration-resistant prostate cancer (mCRPC)
• FDA-approved indications for olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide for mCRPC; appropriate selection of a PARP inhibitor/secondary hormonal therapy combination for individual patients
• Published data from the Phase III AMPLITUDE trial evaluating the addition of niraparib to abiraterone/prednisone for mHSPC harboring alterations in HRR genes; recent FDA approval for patients with BRCA2-mutated disease
• Emerging positive findings from the Phase III TALAPRO-3 study assessing talazoparib in combination with enzalutamide versus placebo and enzalutamide for HRR-altered mHSPC
• Mechanistic similarities and differences between saruparib and other PARP inhibitors; ongoing efforts evaluating saruparib for mHSPC and in earlier settings

MODULE 4: Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath

• Biological justification for targeting the PI3K/AKT/mTOR pathway with capivasertib in prostate cancer; rationale for benefit in patients with PTEN-deficient disease
• Frequency of PTEN deficiency in prostate cancer; indications for and optimal timing of and approach to PTEN assessment
• Design, eligibility criteria and primary and secondary endpoints of the Phase III CAPItello-281 trial assessing capivasertib with abiraterone/ADT for patients with de novo mHSPC and PTEN deficiency
• Recently presented positive results from CAPItello-281 with the addition of capivasertib to abiraterone/ADT for PTEN-deficient mHSPC
• Spectrum of toxicities associated with capivasertib; recommended monitoring and management strategies
• Potential integration of capivasertib/abiraterone/ADT into mHSPC treatment algorithms; optimal use compared to other currently available regimens

MODULE 5: Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad

• Incidence of prostate specific membrane antigen (PSMA) expression in prostate cancer; current utility in detecting metastatic progression and as a therapeutic target
• Published Phase III datasets with lutetium Lu 177 vipivotide tetraxetan for patients with taxane-naïve and taxane-pretreated, PSMA-positive mCRPC; appropriate sequencing opposite other available therapies
• Recently presented results from the Phase III PSMAddition study evaluating the addition of lutetium Lu 177 vipivotide tetraxetan to hormonal therapy for patients with PSMA-positive mHSPC; implications for clinical practice
• Tolerability/toxicity profile of lutetium Lu 177 vipivotide tetraxetan alone and in combination with AR-targeted therapy/ADT
• Early findings with and ongoing evaluation of other novel radiopharmaceuticals for mPC

Target Audience
This activity has been designed to meet the educational needs of urologists, medical and radiation oncologists, and other allied healthcare professionals involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

• Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate treatment plans for individual patients considering the potential benefits and risks of new and established forms of hormonal therapy. 
• Appraise published research findings on optimal management approaches for biochemical recurrence after local treatment for prostate cancer, and counsel appropriate patients regarding the potential benefits of FDA-approved systemic treatment options. 
• Evaluate the published research database supporting the FDA approvals of secondary hormonal agents for the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options. 
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into current clinical management algorithms. 
• Assess the available research database supporting the use of PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms. 
• Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway for prostate cancer, and evaluate available data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency. 
• Review available Phase III data documenting the efficacy of various forms of radioligand therapy for metastatic prostate cancer, and consider the current and future clinical role of these strategies. 
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Agarwal has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Petrylak — Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Exelixis Inc, Gilead Sciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics Inc, Monopteros Therapeutics, Pfizer Inc, pharmaand GmbH, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Ferring Pharmaceuticals, Genentech, a member of the Roche Group, Gilead Sciences Inc, Innocrin Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Mirati Therapeutics Inc, Novartis, Pfizer Inc, pharmaand GmbH, Progenics Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, Sanofi, Seagen Inc. Dr Saad — Advisory Committees and Consulting Agreements: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Johnson & Johnson, Merck, Novartis, Pfizer Inc, Tolmar; Contracted Research: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Johnson & Johnson, Merck, Novartis, Pfizer Inc; Nonrelevant Financial Relationships: Unicancer European Prostate Cancer Consortium (PEACE). Dr Shore — Consulting Agreements: Accord Healthcare, Alessa Therapeutics, Amgen Inc, Asieris Pharmaceuticals, Astellas, AstraZeneca Pharmaceuticals LP, Aura Biosciences Inc, Bayer HealthCare Pharmaceuticals, BioProtect, Bristol Myers Squibb, CG Oncology, Clarity Pharmaceuticals, Dendreon Pharmaceuticals Inc, Ferring Pharmaceuticals, FIZE Medical, GlyTherix, ImmunityBio, Incyte Corporation, Invitae, Janssen Biotech Inc, Lantheus, Lilly, Mdxhealth, Merck, Minomic, Myriad Genetic Laboratories Inc, Novartis, Nusano, Pfizer Inc, Photocure, Promaxo, Protara Therapeutics, Sumitomo Pharma America, Telix Pharmaceuticals Limited, Tolmar, Tutelix, UroGen Pharma; Stock Options/Stock — Public Company: Photocure; Nonrelevant Financial Relationships: PlatformQ Health.

CONSULTING CLINICAL INVESTIGATORS
Andrew J Armstrong, MD, ScM — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Merck, Pfizer Inc, Precede Biosciences, Sumitomo Pharma America, Telix Pharmaceuticals Limited; Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Novartis, Pfizer Inc; Contracted Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, FibroGen Inc, Janssen Biotech Inc, Merck, Novartis, Pathos, Pfizer Inc. Rana R McKay, MD FASCO — Advisory Committees and Consulting Agreements: Ambrx, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Boundless Bio, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Janssen Biotech Inc, Lilly, Merck, Myovant Sciences, Neomorph, Nimbus Therapeutics, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: Artera, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Incyte Corporation, Natera Inc, Oncternal Therapeutics. Joyce O’Shaughnessy — Advisory Committees and Consulting Agreements: Aadi Bioscience, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Ellipses Pharma, Exact Sciences Corporation, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, HiberCell, Jazz Pharmaceuticals Inc, Johnson & Johnson, Lilly, Menarini Group, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, RayzeBio, Roche Laboratories Inc, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Summit Therapeutics, Tempus, TerSera Therapeutics LLC. Sandy Srinivas, MD — Advisory Committees: Janssen Biotech Inc, Merck; Contracted Research: Bristol Myers Squibb, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Johnson & Johnson.

MODERATOR
Dr Heath — Advisory Committees: (Personal Compensation): AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, EMD Serono Inc, Gilead Sciences Inc, Novartis, Petauri Kinect, Pfizer Inc, Sanofi, Seagen Inc, Sumitomo Pharma America; Advisory Committees (to Institution): Janssen Biotech Inc; Consulting Agreements (Personal Compensation): Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Novartis, Sanofi; Consulting Agreements (to Institution): AstraZeneca UK, Novartis; Contracted Research (Grants): K36 Therapeutics, Novartis; Contracted Research (Research Support to Institution): Amgen Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Corcept Therapeutics Inc, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeos Therapeutics, Janssen Research and Development, K36 Therapeutics, Merck, MSD, Mirati Therapeutics Inc, Modra Pharmaceuticals, Novartis, Oncolys Biopharma, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Roche Laboratories Inc, Seagen Inc; Presenter/Co-Moderator: Curio Science; Speakers Bureaus: Sanofi; Steering Committees (Uncompensated): ORIC Pharmaceuticals; Travel Support: AstraZeneca UK; Nonrelevant Financial Relationships: Calibr-Skaggs Institute for Innovative Medicines.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.

Walter E Washington Convention Center
801 Allen Y Lew Place NW
Washington, DC 20001
Phone: (202) 249-3000

Meeting Room
Ballroom A, Third Level

Directions
The Walter E Washington Convention Center is the main venue for the 2026 AUA Annual Meeting.

Registration is now closed.

Part 1 of a 2-Part CME Satellite Symposium Series Held in Conjunction with the 2026 American Urological Association Annual Meeting (AUA2026)

Location
Walter E Washington Convention Center
801 Allen Y Lew Place NW
Washington, DC 20001
Phone: (202) 249-3000

Program Schedule — Eastern Time
7:30 AM – 8:00 AM — Registration and Breakfast
8:00 AM – 9:30 AM — Educational Meeting

Meeting Room
Ballroom A, Third Level

No registration fee is charged for this event. For the in-person symposium in Washington, DC, preregistration is required to ensure seating.

Faculty

Program Schedule — Eastern Time
7:30 AM – 8:00 AM — Registration and Breakfast
8:00 AM – 9:30 AM — Educational Meeting

MODULE 1: Current Indications for Adjuvant Immune Checkpoint Inhibitor Therapy in the Management of Renal Cell Carcinoma (RCC) — Dr Singer

• Appropriate risk stratification for patients with localized RCC
• Outcomes achieved with historical standards of care for localized RCC; biological rationale for the assessment of immune checkpoint inhibitors as adjuvant therapy
• Key efficacy findings from the Phase III KEYNOTE-564trial evaluating pembrolizumab versus placebo as adjuvant treatment for patients with clear cell RCC at increased risk of recurrence after nephrectomy; current clinical role of this strategy
• Published data from Phase III studies, such as IMmotion010, CheckMate 914 Parts A and B, RAMPART and PROSPER RCC, demonstrating a lack of benefit with other (neo)adjuvant immune checkpoint inhibitor-based strategies for patients with RCC; efficacy advantages, if any, observed in specific subsets in these studies

MODULE 2: Potential Role of Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitors as a Component of Adjuvant Treatment — Dr Hutson

• Biological rationale for targeting HIF-2α in patients with RCC; mechanism of action of belzutifan
• Outcomes achieved with belzutifan for patients with advanced RCC and for those with von Hippel-Lindau-associated disease; current clinical role of this agent
• Proposed synergy between belzutifan and PD-1 blockade by pembrolizumab
• Recently presented findings from the Phase III LITESPARK-022 trial assessing the addition of belzutifan to pembrolizumab in the adjuvant setting for patients with high-risk clear cell RCC; potential clinical role of this strategy

MODULE 3: Tolerability of Current and Emerging Adjuvant Approaches for RCC — Dr Vaishampayan

• Incidence and spectrum of immune-mediated and other adverse events observed with adjuvant pembrolizumab for patients with RCC; recommended monitoring and management
• Relative and absolute contraindications to the use of immune checkpoint inhibitor therapy; role, if any, in treatment for patients with autoimmune disease or a history of transplant
• Spectrum, frequency, severity and management of toxicities associated with belzutifan
• Tolerability profile of belzutifan and pembrolizumab in combination in the LITESPARK-022 study

Target Audience
This activity has been designed to meet the educational needs of urologists, medical and radiation oncologists and other allied healthcare professionals involved in the treatment of renal cell carcinoma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Optimize the current and future use of adjuvant therapy for patients with RCC, considering the influence of various clinical and biological factors.
• Evaluate available clinical research data with adjuvant anti-PD-1/PD-L1 antibody therapy for patients with RCC at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions, and provide appropriate counsel regarding guideline-endorsed treatment recommendations.
• Understand the biological rationale for the investigation of anti-PD-1/PD-L1 antibody therapy in combination with hypoxia-inducible factor 2 alpha inhibitors as adjuvant therapy for RCC, and consider available trial findings with and the potential role of this novel approach in clinical practice.
• Discern the side effects and toxicities associated with available and investigational therapies used as adjuvant therapy for patients with RCC, and identify strategies to manage and mitigate them.
• Recall ongoing trials evaluating novel agents and strategies as adjuvant therapy for RCC, and use this information to refer candidates for study participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantor.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Singer has no relevant financial relationship to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Vaishampayan — Advisory Committees: AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Pfizer Inc; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Exelixis Inc, Janssen Biotech Inc, Kowa Pharmaceuticals America, Merck, Novartis; Contracted Research: Merck; Nonrelevant Financial Relationships: SWOG.

CONSULTING CLINICAL INVESTIGATORS
Andrew J Armstrong, MD, ScM — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Merck, Pfizer Inc, Precede Biosciences, Sumitomo Pharma America, Telix Pharmaceuticals Limited; Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Novartis, Pfizer Inc; Contracted Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, FibroGen Inc, Janssen Biotech Inc, Merck, Novartis, Pathos, Pfizer Inc Robert J Motzer, MD. Rana R McKay, MD, FASCO — Advisory Committees and Consulting Agreements: Ambrx, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Boundless Bio, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Janssen Biotech Inc, Lilly, Merck, Myovant Sciences, Neomorph, Nimbus Therapeutics, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: Artera, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Incyte Corporation, Natera Inc, Oncternal Therapeutics. Robert J Motzer, MD — Contracted Research: Bristol Myers Squibb, Eisai Inc, Exelixis Inc, Merck. Sandy Srinivas, MD — Advisory Committees: Janssen Biotech Inc, Merck; Contracted Research: Bristol Myers Squibb, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Johnson & Johnson.

MODERATOR
Dr Hutson — Advisory Committees, Consulting Agreements, Contracted Research and Speakers Bureaus: Astellas, AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Exelixis Inc, Merck, Pfizer Inc, Seagen Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by an educational grant from Merck.

Walter E Washington Convention Center
801 Allen Y Lew Place NW
Washington, DC 20001
Phone: (202) 249-3000

Meeting Room
Ballroom A, Third Level

Directions
The Walter E Washington Convention Center is the main venue for the 2026 AUA Annual Meeting.

Registration is now closed.

Faculty

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Biology and Current Management of Hormone-Receptor (HR)-Positive Metastatic Breast Cancer (mBC); Clinical Relevance of ESR1 Mutations

• Incidence, pathophysiology and clinical characteristics of HR-positive mBC
• Current role of endocrine-based therapies in the management of HR-positive mBC; known mechanisms of resistance to hormonal therapy
• Prevalence of ESR1 mutations in HR-positive, HER2-negative mBC; relevance of prior therapeutic exposure
• Optimal timing and approach to testing for ESR1 mutations in patients with HR-positive, HER2-negative mBC
• Role of oncology nurses in facilitating assessment for ESR1 status in patients with HR-positive, HER2-negative mBC and in helping them understand the implications of results

MODULE 2: Current Role of Oral Selective Estrogen Receptor Degraders (SERDs) in Therapy for HR-Positive mBC

• Mechanistic similarities and differences between fulvestrant and the various available and investigational oral SERDs; implications for efficacy and tolerability
• Published efficacy outcomes with elacestrant for patients with progressive HR-positive, HER2-negative mBC
• Major findings documenting the efficacy of imlunestrant monotherapy for patients with pretreated HR-positive, HER2-negative mBC
• FDA approvals of elacestrant and imlunestrant for patients with previously treated HR-positive, HER2-negative mBC and ESR1 mutations
• Identification of patients appropriate for treatment with elacestrant or imlunestrant

MODULE 3: Potential Role of Early Therapeutic Switching from an Aromatase Inhibitor to an Oral SERD After Detection of an Emergent ESR1 Mutation During First-Line Therapy for HR-Positive mBC

• Early-phase data with camizestrant alone for previously treated HR-positive, HER2-negative advanced breast cancer
• Biological rationale for and potential benefit of serial ESR1 testing for patients receiving first-line endocrine therapy
• Design, eligibility criteria and key efficacy and safety findings from the Phase III SERENA-6 study evaluating a switch from an aromatase inhibitor to camizestrant after detection of an emergent ESR1 mutation during first-line therapy for HR-positive, HER2-negative mBC
• Potential role of serial ESR1 testing and early therapeutic switching for patients found to harbor ESR1 mutations

MODULE 4: Potential Role of Combination Approaches with Oral SERDs for HR-Positive, HER2-Negative Breast Cancer

• Biological rationale for combining oral SERDs with other systemic therapies, such as CDK4/6 inhibitors or PI3K/AKT/mTOR inhibitors
• Efficacy and safety outcomes documented with imlunestrant/abemaciclib for patients with HR-positive, HER2-negative advanced breast cancer with and without ESR1 mutations
• Recently presented data comparing giredestrant in combination with everolimus to standard endocrine therapy with everolimus for pretreated HR-positive, HER2-negative mBC
• Potential role of oral SERD-containing combination regimens and identification of patients appropriate for this approach
• Ongoing assessments of other oral SERD-based strategies for patients with HR-positive breast cancer

MODULE 5: Tolerability of Currently Approved and Investigational Oral SERDs

• Spectrum, frequency and severity of common class-effect toxicities, such as gastrointestinal (GI) side effects, musculoskeletal pain, fatigue and myelosuppression, documented with oral SERDs; comparative tolerability of elacestrant and imlunestrant
• Recommended prophylaxis, monitoring and management of GI toxicities associated with oral SERDs
• Pathophysiology of hyperlipidemia observed with elacestrant and imlunestrant; optimal lipid-profile monitoring for patients receiving either agent
• Incidence and severity of anemia and hypocalcemia noted with imlunestrant versus other oral SERDs; appropriate monitoring for and management of laboratory-value abnormalities in patients receiving these agents

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate the incidence and clinical implications of ESR1 mutations in endocrine-resistant metastatic breast cancer (mBC), and determine optimal strategies to effectively identify patients harboring these abnormalities.
• Understand the biological rationale for, mechanism of action of and pharmacologic similarities and differences among available and investigational oral selective estrogen receptor degraders (SERDs).
• Interrogate published research documenting the efficacy of oral SERD monotherapy in patients with hormone receptor (HR)-positive, HER2-negative mBC with ESR1 mutations who experience disease progression on standard endocrine therapy in combination with a CDK4/6 inhibitor, in order to optimally understand the role of these agents in patient care.
• Review available research findings with serial ESR1 testing using ctDNA as a means to inform early therapeutic switching for patients with HR-positive mBC receiving CDK4/6 inhibitor-based first-line therapy, and consider the clinical applicability of this novel strategy.
• Evaluate available clinical trial data with oral SERDs in combination with other systemic therapies, such as CDK4/6 inhibitors or mTOR inhibitors, and consider the potential role of these regimens.
• Appreciate side effects associated with available and investigational oral SERDs, and use this information to develop supportive management plans for patients receiving this form of therapy.
• Assess ongoing clinical research evaluating novel applications of oral SERDs for HR-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/OralSERDsMetastaticBreastCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ms Ledezma — Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Pfizer Inc; Steering Committees: AstraZeneca Pharmaceuticals LP. Dr Marti-Smith — Consulting Agreements: Amplity; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, Oncology Nursing News. Dr O’Regan — Advisory Committees: Biotheranostics Inc, A Hologic Company; Consulting Agreements: Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, Regor Pharmaceuticals; Contracted Research: Novartis, Puma Biotechnology Inc; Data and Safety Monitoring Boards/Committees: Gilead Sciences Inc.

MODERATOR — Dr McArthur — Advisory Committees: Arvinas, AstraZeneca Pharmaceuticals LP, Boston Scientific Corporation, Celcuity, Daiichi Sankyo Inc, Delcath Systems Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc; Consulting Agreements: ALX Oncology.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP, Lilly, and Stemline Therapeutics Inc.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Program Schedule — Central Time
5:30 AM – 6:00 AM — Registration and Breakfast
6:00 AM – 7:30 AM — Educational Meeting

MODULE 1: Appropriate Risk Assessment for Patients with Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer; Rationale for the Use of CDK4/6 Inhibitors for Those at High Risk for Recurrence

• Clinicopathologic factors (eg, age, tumor size and grade, nodal involvement) affecting the risk of recurrence for patients with HR-positive, HER2-negative localized breast cancer
• Long-term outcomes achieved with standard adjuvant endocrine therapy with or without chemotherapy for patients with HR-positive, HER2-negative localized breast cancer, including those at high risk for recurrence
• Mechanism of antitumor activity of CDK4/6 inhibitors; similarities and differences among available agents in this class
• Rationale for the addition of CDK4/6 inhibitors to standard adjuvant endocrine therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer

MODULE 2: Role of Adjuvant CDK4/6 Inhibitor Therapy for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer

• Extended follow-up, including recently published overall survival outcomes, with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer
• Five-year outcomes with ribociclib and endocrine therapy compared to endocrine therapy alone as adjuvant treatment for high-risk, HR-positive, HER2-negative localized breast cancer
• FDA-approved indications and identification of appropriate candidates for adjuvant abemaciclib and ribociclib

MODULE 3: CDK4/6 Inhibitors for HR-Positive Metastatic Breast Cancer (mBC)

• Long-term follow-up data with abemaciclib, palbociclib and ribociclib for patients with HR-positive mBC
• Factors affecting the selection of a CDK4/6 inhibitor and an endocrine partner for premenopausal and postmenopausal patients
• Role of CDK4/6 inhibitors in treatment for unique patient populations, such as those with aggressive visceral disease and those with CNS metastases
• Available data on the utility of continuing CDK4/6 inhibitors beyond progression or rechallenge in later lines of therapy; current role of this strategy in clinical practice

MODULE 4: Cytopenias Associated with CDK4/6 Inhibitors

• Similarities and differences in the tolerability profiles of abemaciclib, palbociclib and ribociclib; spectrum and frequency of commonly occurring class-effect toxicities, such as cytopenias, gastrointestinal (GI) events and fatigue
• Appropriate monitoring of complete blood counts during CDK4/6 inhibitor therapy
• Thresholds for dose modification, treatment interruption and treatment discontinuation for patients experiencing cytopenias on CDK4/6 inhibitor therapy

MODULE 5: GI Adverse Events Documented with CDK4/6 Inhibitors

• Rates of various GI issues (eg, diarrhea, nausea and vomiting, constipation, abdominal pain) in patients receiving CDK4/6 inhibitor therapy
• Indications for antidiarrheals and/or antiemetics for patients receiving CDK4/6 inhibitors
• Role of nutritional counselling and diet modifications in CDK4/6 inhibitor treatment

MODULE 6: Rarer but Potentially Serious Toxicities Associated with 1 or More CDK4/6 Inhibitors

• Incidence of interstitial lung disease/pneumonitis associated with CDK4/6 inhibitor therapy; recommended algorithms for monitoring, mitigation and management
• Frequency and severity of hepatotoxicity documented with CDK4/6 inhibitors; appropriate monitoring of liver function tests before and during treatment
• Rates of venous thromboembolic events (VTE) reported with CDK4/6 inhibitor therapy; optimal monitoring for signs of VTE and precautionary measures for patients with preexisting risk factors
• Severe cutaneous adverse reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms) documented with CDK4/6 inhibitors; role of dermatologic consultation in the care of patients with signs or symptoms
• Incidence of cardiac toxicity with ribociclib; appropriate use of electrocardiogram monitoring before and during therapy

MODULE 7: Practical Considerations with CDK4/6 Inhibitors

• Optimal dosing and dose-adjustment strategies with CDK4/6 inhibitors for patients with localized and metastatic breast cancer
• Recommended duration of CDK4/6 inhibitor therapy in the adjuvant setting
• Approaches for encouraging and assessing adherence for patients receiving CDK4/6 inhibitor therapy
• Drug-drug interactions noted with 1 or more CDK4/6 inhibitors

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Discern the mechanism by which the cyclin-dependent kinase (CDK) pathway contributes to breast cancer proliferation and growth, and consider the implications for the management of hormone receptor (HR)-positive disease.
• Understand how various clinical and biological factors, such as age or menopausal status, tumor size or grade and nodal involvement, affect the risk of disease recurrence, and use this information to personalize the selection of adjuvant systemic therapy for patients with newly diagnosed HR-positive, HER2-negative localized breast cancer.
• Consider available clinical trial findings with CDK4/6 inhibitors for localized HR-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents would be appropriate.
• Appraise published findings from randomized clinical trials establishing the efficacy and safety of CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer in order to understand the risks, benefits and optimal clinical use of these agents in various patient subgroups.
• Recognize adverse events and other common side effects associated with different CDK4/6 inhibitors for breast cancer, and tailor therapy for patients with preexisting medical conditions and relevant comorbidities.
• Develop preventive and emergent strategies to reduce or ameliorate the various toxicities associated with CDK4/6 inhibitors.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/CDKiHRPositiveBreastCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Fischer has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Marti-Smith — Consulting Agreements: Amplity; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, Oncology Nursing News. Dr O’Regan — Advisory Committees: Biotheranostics Inc, A Hologic Company; Consulting Agreements: Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, Regor Pharmaceuticals; Contracted Research: Novartis, Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.

MODERATOR — Dr Nanda — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Relay Therapeutics.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Lilly and Novartis.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Program Schedule — Central Time

11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

MODULE 1: Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

• Rationale for targeting B-cell maturation antigen (BCMA) with CAR T-cell therapy for MM
• Research database documenting the effectiveness of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for heavily pretreated MM
• Available data with and FDA approvals of ide-cel and cilta-cel in earlier settings; overall survival (OS) advantage documented with cilta-cel
• Identification of appropriate candidates for BCMA-targeted CAR T-cell therapy and optimal sequencing of this strategy opposite other evidence-based approaches
• Early data with and ongoing evaluation of CAR T-cell platforms with targets beyond BCMA (eg, the GPRC5D-directed agent arlocabtagene autoleucel)

MODULE 2: Tolerability and Other Practical Considerations with CAR T-Cell Therapy

• Overview of the CAR T-cell manufacturing and delivery processes
• Incidence, timing and signs and symptoms of cytokine release syndrome (CRS), neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANS) and other acute adverse events (AEs) with CAR T-cell therapy; optimal patient monitoring after infusion
• Guideline-endorsed approaches for mitigation and management of CRS, neurotoxicity/ICANS and other AEs with CAR T-cell therapy; role of corticosteroids, tocilizumab and other supportive care interventions
• Educating patients about practical requirements after CAR T-cell infusion (eg, the need to remain within proximity of the treatment center, recommendations regarding driving); implications of the recent elimination of the Risk Evaluation and Mitigation Strategy program for CAR T-cell therapy
• Potential for long-term tolerability/toxicity concerns (eg, delayed neurotoxicity, prolonged cytopenias, hypogammaglobulinemia, infections, secondary malignancies) with CAR T-cell therapy

MODULE 3: Role of B-Cell Maturation Antigen (BCMA)- and Non-BCMA-Targeted Bispecific Antibodies for MM

• Mechanistic similarities and differences between bispecific antibodies and CAR T-cell therapy; targets of various approved bispecific antibodies (eg, teclistamab, elranatamab, linvoseltamab, talquetamab)
• Long-term outcomes observed in pivotal trials of the BCMA-targeted bispecific antibodies teclistamab and elranatamab for heavily pretreated MM
• Efficacy and safety data leading to the FDA approval of the anti-BCMA bispecific antibody linvoseltamab for R/R MM
• Available efficacy and safety data with the non-BCMA-targeted bispecific antibody talquetamab for heavily pretreated disease
• Optimal selection of candidates with R/R MM for BCMA- and non-BCMA-targeted bispecific antibodies; considerations guiding the sequencing of these agents relative to other strategies and each other

MODULE 4: Toxicities and Practical Issues Related to Bispecific Antibodies

• Potential practical advantages of the “off-the-shelf” nature of bispecific antibodies
• Routes of administration, recommended dosing schedules and premedications with the various bispecific antibody platforms for MM; duration of hospitalization during step-up dosing
• Comparative tolerability of BCMA- and non-BCMA-directed bispecific antibodies for MM
• Incidence, severity and time course of CRS and neurotoxicity with bispecific antibodies; recommended protocols for mitigation and management
• Spectrum, frequency and management of other toxicities (eg, hepatotoxicity, infections, neutropenia, skin- and nail-related AEs, oral toxicities) reported with one or more bispecific antibodies

MODULE 5: Utility of Belantamab Mafodotin for R/R MM

• Mechanism of action and structural components of the BCMA-directed antibody-drug conjugate belantamab mafodotin
• Historical efficacy and safety findings with belantamab mafodotin monotherapy for patients with R/R MM; rationale for the withdrawal of this agent
• Key findings with belantamab mafodotin in combination with bortezomib/dexamethasone and pomalidomide/dexamethasone for patients who have received ≥1 prior line of therapy; OS advantage documented with the former combination
• Ongoing FDA review of belantamab mafodotin-based combination strategies; potential clinical role for R/R MM

MODULE 6: Tolerability Considerations with Belantamab Mafodotin

• Pathophysiology and symptomatology of the ocular AEs observed with belantamab mafodotin; impact of dosing on frequency and severity of ocular AEs
• Indications for and timing of ophthalmologic referral for patients about to receive belantamab mafodotin
• Optimal approaches to the management of ocular toxicities with belantamab mafodotin
• Spectrum, frequency, severity and management of other common and uncommon toxicities reported with belantamab mafodotin

MODULE 7: Potential Role of Cereblon E3 Ligase Modulators (CELMoDs) for MM

• Mechanism of action of the CELMoDs iberdomide and mezigdomide; similarities and differences between CELMoDs and standard immunomodulatory agents (IMiDs)
• Published efficacy and safety findings with iberdomide and mezigdomide as monotherapy and combined with other systemic therapies for pretreated MM
• Rationale for the use of minimal residual disease (MRD) negativity as a clinical trial endpoint for MM; emerging Phase III data indicating an improvement in MRD negativity rates with iberdomide/daratumumab/dexamethasone versus daratumumab/bortezomib/dexamethasone for R/R MM
• Other ongoing studies evaluating CELMoD-containing therapy for newly diagnosed and R/R MM; potential clinical role of CELMoDs

MODULE 8: Tolerability/Toxicity Considerations with CELMoDs for MM

• Comparative tolerability profiles of iberdomide, mezigdomide and traditional IMiDs
• Spectrum, frequency and severity of hematologic AEs observed with CELMoDs in published clinical studies
• Incidence and time course of nonhematologic complications (eg, gastrointestinal toxicities, cutaneous AEs, fatigue, infections, peripheral neuropathy) reported with CELMoDs
• Toxicity and tolerability of iberdomide and mezigdomide in combination with other effective antimyeloma therapies; strategies to discern the effects of each individual agent
• Appropriate monitoring, mitigation and management protocols for hematologic and nonhematologic side effects with CELMoDs

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Consider published research findings and other clinical factors that affect the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with relapsed/refractory (R/R) multiple myeloma (MM).
• Evaluate the biological rationale for chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy in MM, and discuss with patients when and if this novel strategy should be considered.
• Educate patients with R/R MM about the mechanism of action of, available data with and current clinical role of BCMA- and non-BCMA-directed bispecific antibodies.
• Review recently presented clinical research findings establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy, and recognize the potential clinical role of this form of treatment.
• Appreciate the mechanism of action of, unique characteristics of and available and emerging data with the various cereblon E3 ligase modulators under development, to prepare for their potential clinical availability for patients with R/R MM.
• Implement a plan of care to recognize and manage side effects and toxicities associated with commonly used, recently approved and promising emerging systemic therapies for MM.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/RRMultipleMyeloma/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Faiman — Advisory Committees and Consulting Agreements: Janssen Biotech Inc, Sanofi. Dr Lee — Consulting Agreements (Paid to Institution): AbbVie Inc, Alexion Pharmaceuticals, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Legend Biotech, Medline, Pfizer Inc, Predicta Biosciences, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Consulting Agreements (Paid to Self): Alexion Pharmaceuticals, Allogene Therapeutics, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Moderna, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Allogene Therapeutics, Takeda Pharmaceuticals USA Inc. Dr Steinbach — Advisory Committees: Bristol Myers Squibb, Johnson & Johnson, Pfizer Inc, Regeneron Pharmaceuticals Inc; Contracted Research and Speakers Bureaus: Johnson & Johnson, Pfizer Inc, Regeneron Pharmaceuticals Inc.

MODERATOR — Dr Callander has no relevant financial relationships to disclose.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 8:00 PM — Educational Meeting

MODULE 1: Current Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma (NHL)

• Design of bispecific antibodies to engage 2 disease targets with 1 molecule; potential therapeutic advantages over traditional monoclonal antibodies
• Scientific rationale for the selection of CD20 and CD3 as targets for bispecific antibodies in NHL; mechanism of antitumor activity
• Pharmacological similarities and differences among the various approved (eg, glofitamab, epcoritamab, mosunetuzumab) and investigational (eg, odronextamab) CD20 x CD3 bispecific antibodies for NHL; implications for efficacy, tolerability and ease of use
• Similarities and differences between bispecific antibodies and chimeric antigen receptor T-cell therapy
• FDA-approved indications for mosunetuzumab, glofitamab and epcoritamab; optimal selection and sequencing of bispecific antibodies for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

MODULE 2: Tolerability Concerns with Bispecific Antibodies for NHL

• Pathophysiology of the CRS and neurotoxicity observed with bispecific antibody therapy, including immune effector cell-associated neurotoxicity syndrome (ICANS)
• Comparative incidence and severity of CRS with bispecific antibodies available for various NHL subtypes
• Common signs and symptoms and typical course of CRS
• Clinical presentation of neurotoxicity/ICANS and common symptoms, such as delirium, dysphasia, lethargy, difficulty concentrating and confusion
• Guideline-endorsed approaches for monitoring, mitigation and management of CRS and neurotoxicity; role of corticosteroids, tocilizumab and other supportive care interventions
• Spectrum, frequency and severity of other common tolerability concerns, such as cytopenia, infections, fatigue, rash, musculoskeletal pain and gastrointestinal (GI) adverse events (AEs), with bispecific antibodies for patients with NHL

MODULE 3: Role of Polatuzumab Vedotin in Therapy for DLBCL

• Structural components of polatuzumab vedotin and mechanism of antitumor activity
• Extended follow-up with polatuzumab vedotin/R-CHP (rituximab, cyclophosphamide, doxorubicin and prednisone) for previously untreated DLBCL
• Current role of polatuzumab vedotin as a component of up-front therapy for DLBCL; appropriate selection of candidates for this strategy
• Efficacy and safety findings with polatuzumab vedotin in combination with chemoimmunotherapy (bendamustine/rituximab, rituximab/gemcitabine/oxaliplatin) or bispecific antibodies (mosunetuzumab) for patients with relapsed/refractory (R/R) DLBCL; current and potential role of these regimens

MODULE 4: Tolerability Considerations with Polatuzumab Vedotin

• Rates and severity of peripheral neuropathy with polatuzumab vedotin; appropriate use of dose adjustments and other management strategies
• Incidence of cytopenias and infections with polatuzumab vedotin-containing regimens; appropriate monitoring of complete blood counts (CBCs) during therapy
• Spectrum and incidence of GI AEs with polatuzumab vedotin-based therapy; strategies for management
• Differences, if any, in the tolerability of polatuzumab vedotin in the up-front versus the R/R setting; implications for AE monitoring and management

MODULE 5: Optimal Application of Loncastuximab Tesirine for Patients with DLBCL or FL

• Mechanism of action and structural makeup of the anti-CD19 antibody-drug conjugate loncastuximab tesirine
• Long-term findings with loncastuximab tesirine for R/R DLBCL; patient selection and optimal sequencing
• Available data with loncastuximab tesirine in combination with other therapies and for other NHL subtypes
• Recent NCCN guideline inclusion of loncastuximab tesirine/rituximab as a third- or later-line treatment option for FL; optimal incorporation into practice

MODULE 6: Tolerability Considerations with Loncastuximab Tesirine

• Incidence, severity and management of edema and effusions with loncastuximab tesirine
• Rates of myelosuppression and infections with loncastuximab tesirine; appropriate monitoring of CBCs during therapy
• Spectrum of cutaneous reactions documented with loncastuximab tesirine, such as photosensitivity reactions, rash and erythema; recommended strategies for mitigation and management
• Initial dosing and dose-modification strategies with loncastuximab tesirine; recommended premedications, such as dexamethasone and G-CSF, for some or all patients

MODULE 7: Current and Future Role of Covalent and Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitors in the Management of Chronic Lymphocytic Leukemia (CLL)

• Indications for initiating active therapy for patients with previously untreated CLL
• Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for patients with treatment-naïve and R/R CLL; application in current up-front decision-making
• Comparative antitumor activity of BTK inhibitors alone and in combination with anti-CD20 antibodies in the up-front setting; implications for therapy selection

MODULE 8: Tolerability of Covalent and Noncovalent BTK Inhibitors

• Incidence and severity of cardiac arrhythmias, including atrial fibrillation or flutter, documented with approved covalent BTK inhibitors
• Probability of other cardiovascular toxicities, such as stroke, hypertension and bruising or bleeding events, with covalent BTK inhibitor therapy
• Spectrum and frequency of clinically relevant noncardiovascular toxicities, including cytopenias, infections, headache, dermatologic symptoms, arthralgia/myalgia and GI events, with covalent BTK inhibitors
• Appropriate monitoring for and management of treatment-related cardiovascular and noncardiovascular events in patients receiving covalent BTK inhibitors
• Tolerability of pirtobrutinib relative to available covalent BTK inhibitors
• Incidence and severity of cardiac arrhythmias and other cardiovascular and noncardiovascular toxicities documented with pirtobrutinib
• Appropriate monitoring for and management of treatment-related AEs in patients receiving pirtobrutinib
• Safety profile of pirtobrutinib in the front-line setting

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate available research findings with CD20 x CD3 bispecific antibodies for relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), and counsel patients regarding the risks and benefits of this novel approach.
• Recognize the spectrum, frequency and severity of adverse events, such as cytokine release syndrome, neurotoxicity, infections and cytopenias, associated with CD20 x CD3 bispecific antibodies, and consider recommended approaches to prevent, ameliorate and manage these side effects.
• Identify patients with newly diagnosed and R/R DLBCL for whom CD79b-targeted antibody-drug conjugate (ADC) therapy would be appropriate.
• Appraise available research findings with and the current clinical role of CD19-targeted ADCs for patients with R/R DLBCL and FL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with ADCs commonly used in the care of patients with NHL.
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options.
• Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for newly diagnosed and R/R CLL, and identify patients appropriate for treatment with these agents.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review data with and the current and potential role of this strategy for patients with newly diagnosed and R/R CLL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with BTK inhibitors in the management of CLL.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 2 contact hours is provided by Research To Practice.

This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/NHLandCLL/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Klebig and Ms Moran have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Awan — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, DAVA Oncology, Genmab US Inc, Incyte Corporation, Invivyd, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, Pierre Fabre; Contracted Research: Actinium Pharmaceuticals Inc, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Boards/Committees: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Caribou Biosciences Inc.

MODERATOR — Dr Kahl — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc; Contracted Research: BeOne, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeOne, Bristol Myers Squibb, Roche Laboratories Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, and Lilly.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Program Schedule — Central Time

11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

MODULE 1: Identification of Appropriate Candidates with Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC) for Agents Targeting the PI3K/AKT/mTOR Pathway

• Incidence of relevant biomarkers, including alterations along the PI3K/AKT/mTOR pathway, in HR-positive, HER2-negative mBC
• Clinical characteristics associated with PI3K/AKT/mTOR pathway alterations in HR-positive, HER2-negative mBC
• Optimal methodology for and timing of assessment for alterations along the PI3K/AKT/mTOR pathway for HR-positive, HER2-negative mBC
• Role of oncology nurses in facilitating biomarker testing for HR-positive, HER2-negative mBC and helping patients understand the implications of the results

MODULE 2: Role of Inavolisib in the Management of HR-Positive mBC

• Mechanistic similarities and differences between inavolisib and earlier-generation PI3K inhibitors (ie, alpelisib); implications for efficacy and tolerability
• Key findings with inavolisib in combination with palbociclib and fulvestrant as first-line therapy for patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative mBC
• FDA approval of inavolisib/palbociclib/fulvestrant, and current clinical role for newly diagnosed HR-positive, HER2-negative mBC with a PIK3CA mutation
• Ongoing evaluation of inavolisib for endocrine-sensitive, PIK3CA-mutated, HR-positive, HER2-negative mBC; potential role in this setting

MODULE 3: Adverse Events (AEs) Associated with Inavolisib

• Incidence of hyperglycemia with inavolisib; optimal monitoring of fasting glucose levels and HbA1c
• Appropriate management of hyperglycemia occurring with inavolisib; indications for antidiabetic medications and dose modifications
• Incidence of gastrointestinal (GI) toxicities (eg, diarrhea, stomatitis, nausea) with inavolisib; strategies for mitigation and management
• Spectrum, frequency, severity and management of other toxicities (eg, cytopenias, fatigue, rash) documented with inavolisib-containing therapy

MODULE 4: Clinical Utility of Capivasertib in the Management of HR-Positive mBC

• Biological rationale for inhibiting AKT in the management of HR-positive mBC; mechanism of action of capivasertib
• Key efficacy and safety data with capivasertib/fulvestrant for recurrent HR-positive, HER2-negative mBC
• FDA approval of capivasertib for patients with HR-positive, HER2-negative mBC with PIK3CA/AKT1/PTEN alterations, and current role opposite other evidence-based options
• Ongoing evaluation of the triplet combination of capivasertib, fulvestrant and a CDK4/6 inhibitor as first-line therapy for patients with HR-positive, HER2-negative mBC who experience disease progression on or within 12 months of completing (neo)adjuvant endocrine therapy

MODULE 5: Side Effects and Other Practical Considerations with Capivasertib

• Recommended management strategies for patients experiencing diarrhea and other GI disorders while receiving capivasertib
• Pathophysiology, spectrum and optimal treatment of cutaneous adverse reactions with capivasertib
• Incidence of hyperglycemia in patients receiving capivasertib; indications for blood glucose monitoring and role, if any, for patients with preexisting diabetes
• Dose, schedule and recommended approach to dose modifications with capivasertib

MODULE 6: Potential Role of Gedatolisib in the Management of HR-Positive mBC

• Mechanistic similarities and differences between gedatolisib and currently approved therapies targeting the PI3K/AKT/mTOR pathway for HR-positive mBC; implications for antitumor activity
• Recently presented data from the PIK3CA wild-type cohort of a Phase III study evaluating gedatolisib in combination with fulvestrant with or without palbociclib for patients with HR-positive, HER2-negative mBC whose disease progressed on or after prior CDK4/6 inhibitor therapy and an aromatase inhibitor
• Anticipated read-out of the PIK3CA-mutated cohort of the aforementioned study
• Potential role of gedatolisib-containing combination therapy for pretreated HR-positive, HER2-negative mBC that is PIK3CA wild type and PIK3CA mutated

MODULE 7: Tolerability Profile of Gedatolisib

• Rates of treatment discontinuation due to an AE documented with gedatolisib/palbociclib/fulvestrant and gedatolisib/fulvestrant
• Incidence and severity of hyperglycemia and diarrhea with gedatolisib-based therapy relative to other agents targeting the PI3K/AKT/mTOR pathway
• Spectrum and incidence of other treatment-related AEs documented with gedatolisib-based therapy (eg, stomatitis, neutropenia, nausea, vomiting, rash, fatigue)
• Strategies to monitor for, mitigate and manage treatment-related AEs with gedatolisib

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Review available research documenting the correlation between various biomarkers, such as PIK3CA/AKT1/PTEN alterations and ESR1 mutations, and response to specific therapies, and understand optimal testing algorithms for patients with hormone receptor (HR)-positive metastatic breast cancer (mBC).
• Recognize the frequency of PIK3CA/AKT/PTEN alterations in HR-positive mBC, and educate patients with newly diagnosed and relapsed/refractory disease about evidence-based approaches to targeting these aberrations.
• Understand the biological rationale for the development of agents targeting multiple components of the PI3K/AKT/mTOR pathway, and recognize available and emerging data with this strategy for patients with HR-positive, PIK3CA wild-type and PIK3CA-mutant mBC.
• Assess the spectrum, frequency and severity of adverse events associated with available and emerging agents targeting the PI3K/AKT/mTOR pathway, and consider recommended approaches to prevent, ameliorate and manage these side effects.
• Evaluate available research findings with and ongoing studies evaluating novel PI3K/AKT/mTOR inhibitor-based approaches, and consider the potential role of these strategies.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/PI3KAKTmTORMetastaticBreastCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Fischer has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Basho — Advisory Committees: AstraZeneca Pharmaceuticals LP, Celcuity, Novartis, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Scorpion Therapeutics; Data and Safety Monitoring Boards/Committees: Pfizer Inc; Speakers Bureaus: DAVA Oncology, MDOutlook; Nonrelevant Financial Relationships: Community Health Media, OncLive, Targeted Oncology. Ms Rikal — Advisory Committees: Stemline Therapeutics Inc; Consulting Agreements and Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. Additional faculty to be announced.

MODERATOR — Dr Wander — Consulting Agreements: Arvinas, AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Biovica International AB, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Novartis, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics, Stemline Therapeutics Inc, Veracyte Inc; Contracted Research: Arvinas, Genentech, a member of the Roche Group, Lilly, Menarini Group, Nuvation Bio Inc, Pfizer Inc, Phoenix Molecular Designs, Puma Biotechnology Inc, Regor Therapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celcuity, and Genentech, a member of the Roche Group.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.